On the evening of November 28, Beijing time, a number of authoritative foreign media reported that the tennis women's singles world No. 2 and Polish star Swiatek was tested positive for taking the banned substance trimetazidine (TMZ). She has already received a one-month provisional ban that saw her withdraw from the Asian season, just in time to miss the Chinese and Wuhan Opens.
However, Swiatek later successfully appealed and proved her innocence, and she tested positive for drugs only because the controlled drug was contaminated in very low levels, and there was no gross negligence or negligence. With the expiration of the ban, Swiatek will be able to play in the United Cup at the end of the year and the Australian Open early next year.
Born in May 2001, Swiatek won her first French Open title in 2020, becoming the first Polish player in history to win a Grand Slam singles title. In 2022, she made her debut in the women's tennis world No. 1 and as of this year, Swiatek has won five Grand Slam singles titles, including four French Open titles and one US Open. Currently, Swiatek is ranked No. 2 in the world, behind Sabalenka.
It is worth noting that this is not the first tennis superstar in tennis to be caught in a banned drug scandal this year. In March of this year, the men's tennis world No. 1 Sinner was tested for banned drugs twice during the Open in the Dialana Wells.
However, Sinner's appeal was successful, and after escaping the ban, Sinner not only won the Grand Slam title twice this year and won the year-end finals for the first time, but also ranked No. 1 in the world rankings.